THE ASSOCIATION OF EPSTEIN-BARR VIRUS ANTIBODIES WITH RHEUMATOID ARTHRITIS AMONG YEMENI PATIENTS IN SANA’A CITY
Objectives: Rheumatoid arthritis (RA) is a chronic autoimmune disease that is associated with progressive disability, systemic complications and early death. Etiology of RA is unknown. It is assumed that environmental factors initiate RA development in genetically susceptible individuals. Epstein- Barr Virus (EBV) stimulates polyclonal B cell activation and has been suggested to play a role in RA pathogenesis. Current study aimed to study the association between EBV and RA.
Methods: One hundred and sixty subjects were enrolled in the study. Eighty individuals were clinically diagnosed to have RA and confirmed by anti-CCP3 test. The remaining 80 individuals were healthy controls matched for age and sex. Serum IgG and IgM antibodies against EBV viral capsid antigen (VCA) were tested by an enzyme-linked immunosorbent assay (ELISA).
Results: The crude prevalence rate of EBV-VCA IgM antibodies among patients was (21.2%) while in healthy individuals was (8.7%) with significant OR equals to 2.8 times for RA patient's. The female prevalence rate of EBV-VCA IgM antibodies was (21.8%) higher than of male (18.7%). The female prevalence rate of EBV-VCA IgG antibodies was (95.3%) higher than of male (75%). EBV-VCA IgG and IgM antibodies titers were elevated in RA patients than in healthy controls. However, the causative relationship between EBV and RA is complex and involves different mechanisms.
Conclusion: In conclusion, high titers of EBV antibodies are associated with RA. However, the causative relationship between EBV and autoimmune diseases is complex and involves different mechanisms.
Peer Review History:
Received 16 August; Revised 28 August; Accepted 5 September, Available online 15 September 2017
UJPR follows the most transparent and toughest ‘Advanced OPEN peer review’ system. The identity of the authors and, reviewers will be known to each other. This transparent process will help to eradicate any possible malicious/purposeful interference by any person (publishing staff, reviewer, editor, author, etc) during peer review. As a result of this unique system, all reviewers will get their due recognition and respect, once their names are published in the papers. We expect that, by publishing peer review reports with published papers, will be helpful to many authors for drafting their article according to the specifications. Auhors will remove any error of their article and they will improve their article(s) according to the previous reports displayed with published article(s). The main of it is ‘to improve the quality of a candidate manuscript’. Our reviewers check the ‘strength and weakness of a manuscript honestly’. There will increase in the perfection, and transparency.
Average Peer review marks at initial stage: 5.5/10
Average Peer review marks at publication stage: 8.0/10
Name: Dr. Müjde Eryılmaz
Affiliation: Ankara University,Turkey
Name: Dr. Tamer Mohamed Ali ElHabibi
Affiliation: ERU University, Egypt
Comments of reviewer(s):